In June, a European medical safety committee noted that Wegovy and Ozempic have been linked in very rare cases to the eye condition, Reuters reported, which led Novo Nordisk to update its European labels for Wegovy and Ozempic to state that semaglutide, their active ingredient, may cause NAION in up to 1 in 10,000 patients
GLP-1 drugs were originally developed to treat diabetes and obesity
Currently, the peptide is not FDA-approved for human use and it is not a subject of any regulation
By supporting hunger and fullness signaling, Wegovy may help some individuals feel satisfied sooner and support weight-management efforts when combined with appropriate nutrition and lifestyle changes
Levonen, A
Structure, mechanisms, research areas, stability profiles, and purity standards analyzed